metricas
covid
Buscar en
Archivos de la Sociedad Española de Oftalmología (English Edition)
Toda la web
Inicio Archivos de la Sociedad Española de Oftalmología (English Edition) Effect on ocular blood flow of Combigan® versus placebo in patients with ocular...
Journal Information
Vol. 86. Issue 2.
Pages 42-46 (January 2011)
Share
Share
Download PDF
More article options
Vol. 86. Issue 2.
Pages 42-46 (January 2011)
Effect on ocular blood flow of Combigan® versus placebo in patients with ocular hypertension
Efecto de Combigan® versus placebo en el flujo sanguíneo ocular en pacientes hipertensos oculares
Visits
355
B. Puerto-Hernándeza,
Corresponding author
beapuertoh@hotmail.com

Corresponding author.
, G. Rebolledaa, J.L. García-Péreza, F.J. Muñoz-Negretea, C. González-Gordalizab
a Servicio de Oftalmología, Unidad de Glaucoma, IRYCIS, Hospital Ramón y Cajal, Madrid, Spain
b Servicio de Radiodiagnóstico, Hospital Ramón y Cajal, Madrid, Spain
This item has received
Article information
Abstract
Purpose

This study was undertaken to compare the ocular haemodynamic effects of Combigan® versus placebo in patients with ocular hypertension (OHT).

Methods

Thirty patients with OHT were included in a controlled, randomised, double blind study in two parallel groups; 15 were randomised to receive Combigan® and 15 to receive placebo for a period of 3 months. At baseline and at 3 months retrobulbar blood flowmeasurements of the ophthalmic artery (OA) and central retinal artery (CRA) were taken using colour Doppler imaging(CDI) ultrasound, concurrently with intraocular pressure (IOP).

Results

Combigan® significantly reduced IOP after 3 months of treatment (P=0.001), whereas placebo showed no significant change in IOP. The baseline haemodynamic parameters were similar between treatment and placebo groups. Patients treated with Combigan® showed a statistically significant decrease in CRA resistive index (P=0.007).

Conclusions

Patients treated for 3 months with Combigan® showed a significant decrease of CRA resistive index that could be explained by the decrease in IOP

Keywords:
Colour Doppler imagine
Ocular blood flow
Combigan®
Central retinal artery
Ophthalmic artery. Resistive index
Resumen
Propósito

Estudiar los cambios hemodinámicos retrobulbares mediante ecografía doppler color, en pacientes hipertensos oculares (HTO) en tratamiento con Combigan® versus placebo.

Método

Treinta pacientes randomizados en 2 grupos paralelos fueron incluidos en un estudio prospectivo y a doble ciego; quince de ellos en tratamiento con Combigan® y quince en tratamiento con placebo, durante un periodo de 3 meses. Se obtuvieron medidas de la presión intraocular (PIO) y del flujo sanguíneo a nivel de la arteria central de la retina (ACR) y la arteria oftámica en el momento basal y a los 3 meses.

Resultados

Combigan® redujo significativamente la PIO tras tres meses de tratamiento (p=0,001). Los parámetros hemodinámicos basales fueron similares entre los grupos placebo y tratamiento. Los pacientes tratados con Combigan® mostraron un descenso estadísticamente significativo del índice de resistencia de la ACR (p=0,007).

Conclusiones

Los pacientes tratados durante 3. meses con Combigan® mostraron un descenso estadísticamente significativo del índice de resistenciade la ACR que podría explicarse por el descenso de PIO.

Palabras clave:
Ecografía doppler color
Flujo sanguíneo ocular
Combigan®
Arteria central de la retina
Arteria oftálmica
Índice de resistencia

Article

These are the options to access the full texts of the publication Archivos de la Sociedad Española de Oftalmología (English Edition)
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Archivos de la Sociedad Española de Oftalmología (English Edition)

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos